t-C4H9C3H4COCH3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: t-C4H9C3H4COCH3
• 英文别名: 1-(2-Tert-butylcyclopropyl)ethanone
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: WJPIRPGXBGLSIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  t-C4H9C3H4COCH3 、 tributylstannyl radical 生成 t-C4H9C3H4CCH3OSn(C4H9)3
  参考文献：
  名称：

  Castaing, M.; Pereyre, M.; Ratier, M., Journal of the Chemical Society. Perkin transactions II, 1979, p. 589 - 592

  摘要：

  DOI：

文献信息

• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：MENET Christel Jeanne Marie

  公开号：US20150203455A1

  公开（公告）日：2015-07-23

  The present invention discloses compounds according to Formula I: wherein Cy, R 1 , L 1 , R 3 , R 4 , R 5 , L a , and R a are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.

  本发明公开了根据以下公式I的化合物：其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。根据公式I的新型苯并咪唑，能够抑制JAK，这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增殖性疾病、移植排斥反应、涉及软骨周转障碍的疾病、先天性软骨畸形以及与IL6过度分泌或干扰素过度分泌相关的疾病。
• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Smith Nicholas D.

  公开号：US20130231333A1

  公开（公告）日：2013-09-05

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括所述化合物的制药组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物结合，治疗与雌激素受体介导或依赖的疾病或症状的方法。
• Davies, A. G.; Muggleton, B.; Godet, J. Y., Journal of the Chemical Society. Perkin transactions II, 1976, p. 1719 - 1724
  作者：Davies, A. G.、Muggleton, B.、Godet, J. Y.、Pereyre, M.、Pommier, J. C.

  DOI：——

  日期：——
• Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Sn: Org.Comp.12, 1.4.1.1.1.5.16, page 223 - 231
  作者：

  DOI：——

  日期：——
• HEPATITIS C VIRUS INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1505963B1

  公开（公告）日：2011-04-20